Media stories about Evotec (OTCMKTS:EVTCY) have been trending extremely negative recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evotec earned a media sentiment score of -4.36 on their scale. InfoTrie also assigned news articles about the company an news buzz score of 10 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company’s share price in the next few days.
EVTCY traded up $1.06 during trading on Wednesday, hitting $42.64. The company’s stock had a trading volume of 3,025 shares, compared to its average volume of 564. The company has a current ratio of 0.93, a quick ratio of 0.90 and a debt-to-equity ratio of 0.07. Evotec has a one year low of $27.32 and a one year high of $52.50. The company has a market capitalization of $2.91 billion, a PE ratio of 118.44 and a beta of 0.69.
Evotec (OTCMKTS:EVTCY) last released its quarterly earnings results on Thursday, August 9th. The company reported $0.23 earnings per share for the quarter. Evotec had a net margin of 9.57% and a return on equity of 9.45%. The business had revenue of $113.18 million for the quarter. Equities analysts forecast that Evotec will post 0.46 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://weekherald.com/2018/11/07/extremely-critical-press-coverage-extremely-likely-to-impact-evotec-evtcy-share-price.html.
Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services, as well as absorption, distribution, metabolism, excretion, and toxicity services.
Further Reading: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.